Co-administration of MFX and CFZ in children with rifampicin-resistant tuberculosis resulted in greater increases in maximum QTcF and ΔQTcF compared to other MFX- or LFX-based regimens (P=0.0166).
Observational
Does the use of one or more QT-prolonging agents in a multidrug regimen for RR-TB increase the risk of QTcF interval prolongation in children?
The use of QT-prolonging drugs in children with RR-TB carries a low risk of QTcF prolongation, but co-administration of moxifloxacin and clofazimine causes greater QTcF increases.
p-value: p=0.0166
= 0.0166) compared to those when other MFX- or LFX-based regimens were used. In conclusion, we found a low risk of QTcF interval prolongation in children with RR-TB who received at least one QT-prolonging drug. Greater increases in maximum QTcF and ΔQTcF were observed when MFX and CFZ were used together. Future studies characterizing exposure-QTcF responses in children will be helpful to ensure safety with higher doses if required for effective treatment of RR-TB.
Ali et al. (Mon,) conducted a observational in Rifampicin-resistant tuberculosis. Moxifloxacin (MFX) and clofazimine (CFZ) vs. Other MFX- or LFX-based regimens was evaluated on Maximum QTcF and ΔQTcF (p=0.0166). Co-administration of MFX and CFZ in children with rifampicin-resistant tuberculosis resulted in greater increases in maximum QTcF and ΔQTcF compared to other MFX- or LFX-based regimens (P=0.0166).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: